» Articles » PMID: 31544821

Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning

Overview
Date 2019 Sep 24
PMID 31544821
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

CD117 (c-Kit) is a tyrosine kinase receptor that is overexpressed in multiple dog tumors. There is 100% homology between the juxtamembrane domain of human and canine CD117, and many cancer-causing mutations occur in this region in both species. Thus, CD117 is an important target for cancer treatment in dogs and for comparative oncology studies. Currently, there is no monoclonal antibody (mAb) specifically designed to target the exposed region of canine CD117, although there exist some with species cross-reactivity. We panned a naïve phage display library to isolate antibodies against recombinant CD117 on whole cells. Several mAbs were isolated and were shown to bind recombinant canine CD117 at low- to sub-nanomolar affinity. Additionally, binding to native canine CD117 was confirmed by immunohistochemistry and by flow cytometry. Competitive binding assays also identified mAbs that competed with the CD117 receptor-specific ligand, the stem cell factor (SCF). These results show the ability of our cell-based biopanning strategy to isolate a panel of antibodies that have varied characteristics when used in different binding assays. These in vitro/ex vivo assessments suggest that some of the isolated mAbs might be promising candidates for targeting overexpressed CD117 in canine cancers for different useful applications.

Citing Articles

Isolation and Characterization of Antibodies Against Vascular Cell Adhesion Molecule-1 Reveals Putative Role for Ig-like Domains 2 and 3 in Cell-to-Cell Interaction.

Perera B, Wu Y, Pickett J, Panagides N, Barretto F, Fercher C Int J Mol Sci. 2025; 25(24.

PMID: 39769411 PMC: 11678699. DOI: 10.3390/ijms252413650.


Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable () Antibody Selection against Claudin 18.2 via Phage Display.

Effer B, Ulloa D, Dappolonnio C, Munoz F, Iturrieta-Gonzalez I, Cotes L Antibodies (Basel). 2024; 13(1).

PMID: 38534210 PMC: 10967586. DOI: 10.3390/antib13010020.


C-kit, flt-3, PDGFR-β, and VEGFR2 expression in canine adrenal tumors and correlation with outcome following adrenalectomy.

Harding K, de Mello Souza C, Shiomitsu K, Maxwell E, Bertran J Can J Vet Res. 2021; 85(4):279-284.

PMID: 34602732 PMC: 8451711.


Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Alfaleh M, Alsaab H, Mahmoud A, Alkayyal A, Jones M, Mahler S Front Immunol. 2020; 11:1986.

PMID: 32983137 PMC: 7485114. DOI: 10.3389/fimmu.2020.01986.

References
1.
London C . Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med. 2009; 24(3):106-12. DOI: 10.1053/j.tcam.2009.02.002. View

2.
Kim J, Graef A, Dickerson E, Modiano J . Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives. Vet Sci. 2017; 2(4):388-405. PMC: 5644642. DOI: 10.3390/vetsci2040388. View

3.
London C, Hannah A, Zadovoskaya R, Chien M, Kollias-Baker C, Rosenberg M . Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003; 9(7):2755-68. View

4.
Santos R, Ursu O, Gaulton A, Bento A, Donadi R, Bologa C . A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2016; 16(1):19-34. PMC: 6314433. DOI: 10.1038/nrd.2016.230. View

5.
Edling C, Hallberg B . c-Kit--a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007; 39(11):1995-8. DOI: 10.1016/j.biocel.2006.12.005. View